<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583255</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0226</org_study_id>
    <secondary_id>NCI-2018-01103</secondary_id>
    <secondary_id>2018-0226</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>R21NR016737</secondary_id>
    <nct_id>NCT03583255</nct_id>
  </id_info>
  <brief_title>Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Participants With Advanced, Metastatic, or Recurrent Cancer</brief_title>
  <official_title>A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the effects of combining physical
      activity with dexamethasone to treat fatigue in patients with advanced cancer.

      In this study, dexamethasone will be compared to a placebo. A placebo is not a drug. It looks
      like the study drug but is not designed to treat any disease or illness. It is designed to be
      compared with a study drug to learn if the study drug has any real effect.

      This is an investigational study. Dexamethasone is FDA approved and commercially available
      for the treatment of loss of appetite, tiredness, pain, and nausea. It is investigational to
      combine dexamethasone and exercise to treat fatigue in advanced cancer patients. The study
      doctor can explain how the study drug is designed to work.

      Up to 70 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility assessed by the proportion of participants completing the intervention</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will estimate 95% confidence intervals for the proportion of patients completing the intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will be calculated as the mean of the % of total prescribed strength training sessions and the % of total prescribed walking regimen minutes completed (exercise), and mean (across all patients) percentage of total prescribed pills taken (study medication) as detailed above. Will estimate 95% confidence intervals for the proportion of patients completing the intervention and the adherence rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction with PA+DEX</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Patients are satisfied with PA+ DEX, based on more than 75% of patients indicating their satisfaction with PA+ DEX with a rating of &quot;somewhat satisfied&quot; or &quot;completely satisfied&quot; as completed on the Satisfaction Assessment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <condition>Cancer Fatigue</condition>
  <condition>Metastatic Malignant Neoplasm</condition>
  <condition>Recurrent Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (dexamethasone, exercise)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive dexamethasone PO BID for 7 days. Participants also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, exercise)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo PO BID for 7 days. Participants also complete resistance training and moderate intensity walking as in Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (dexamethasone, exercise)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Intervention</intervention_name>
    <description>Complete resistance training and moderate intensity walking</description>
    <arm_group_label>Arm I (dexamethasone, exercise)</arm_group_label>
    <arm_group_label>Arm II (placebo, exercise)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo, exercise)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of advanced cancer (defined as metastatic or recurrent incurable cancer)
             with fatigue &gt;/= 4/10 (0-10 scale) on the Edmonton Symptom Assessment Scale (ESAS)

          2. Presence of fatigue for at least 2 weeks

          3. Normal cognition defined as Memorial Delirium Assessment Scale (MDAS) of &lt;/= 13/30

          4. Hemoglobin &gt;10 g/L within 1 week of enrollment in the study

          5. Zubrod performance status &lt;/= 2

          6. Life expectancy of &gt;/= 4 months

          7. Able to read, write, and speak English.

        Exclusion Criteria:

          1. Patients with a history of hypersensitivity to dexamethasone or having any
             contraindication to physical activity as determined by the treating physician

          2. Reports of a fall in the past 30 days

          3. Diabetes mellitus, sepsis and/or acute, chronic, or ongoing infections that are
             currently being treated with systemic antimicrobials

          4. Current, active peptic ulcer disease

          5. Neutropenia as defined by an absolute neutrophil count (ANC) of &lt; 1000 cells/mm

          6. Regular participation in moderate- or vigorous-intensity physical activity for &gt;/= 30
             minutes at least 5 times a week and strength training for &gt;/= 2 days

          7. Severe cardiac disease (New York Heart Association functional class III or IV) or
             coronary artery disease

          8. Patients currently on immunotherapy

          9. Inability to comply with study protocol procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Yennu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sriram Yennu</last_name>
    <phone>713-792-6085</phone>
    <email>syennu@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sriram Yennu</last_name>
      <phone>713-792-6085</phone>
      <email>syennu@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sriram Yennu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

